SALICYLIC ACID

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name: SALICYLIC ACID
Generic name: SALICYLIC ACID
Manufacturer: Acella Pharmaceuticals, LLC
Product type: HUMAN PRESCRIPTION DRUG
SPL set ID: 572171f7-832f-4710-b888-eef5638fc9d4
SPL ID: 5036e92f-8304-0e9d-e063-6394a90ab3ad
Version: 5
Effective date: 2026-04-24
Source export date: 2026-09-28
Source partition: 8
Source file: https://download.open.fda.gov/drug/label/drug-label-0008-of-0014.json.zip
Source object key: raw/openfda/drug-label/2026-09-28/ae3816359e336a5de4f44607730a3d12ceb61ffa012a132189ceda22541b38ee/drug-label-0008-of-0014.json.zip
Source manifest SHA-256: cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
Import run: 20260929T050834Z
Imported at: 2026-09-29 05:55:27

Harmonized routes table
Harmonized routes
TOPICAL

Harmonized identifier links#

Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.

Harmonized identifiers page 1 of 1 · 10 matching rows.

Type, Scope, Identifier table
Type	Scope	Identifier	Source field
brand name		SALICYLIC ACID	openfda.brand_name
generic name		SALICYLIC ACID	openfda.generic_name
manufacturer name		Acella Pharmaceuticals, LLC	openfda.manufacturer_name
ndc	package	42192-135-10	openfda.package_ndc
ndc	product	42192-135	openfda.product_ndc
ndc11	package	42192013510	derived:openfda.package_ndc
rxcui		1095689	openfda.rxcui
spl id		5036e92f-8304-0e9d-e063-6394a90ab3ad	id
spl set id		572171f7-832f-4710-b888-eef5638fc9d4	set_id
unii		O414PZ4LPZ	openfda.unii

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 1 matching rows.

adverse reactions

ADVERSE REACTIONS: A localized irritant reaction may occur if Salicylic Acid, 27.5% Wart Remover is applied to the normal skin surrounding the wart. Any irritation may normally be controlled by temporarily discontinuing use and by applying the medication only to the wart site when treatment is resumed.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.